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Introduction
In recent years, considerable progress has been made in under-
standing the role of growth factors and cytokines in wound 
healing. These factors are released from injured vessels and co-
agulated platelets and trigger an infl  ammatory response that 
initiates the deposition of a provisional extracellular matrix. In 
parallel, mesenchymal and endothelial precursor cells invade 
the wound to form the granulation tissue and to contract the 
wounded area.
Contraction of the granulation tissue by mesodermal 
fi  broblasts is of high importance for sealing the wound, as it 
helps to bring the wound margins together. To be able to contract 
effi  ciently, mesenchymal cells of the granulation tissue differ-
entiate into myofi  broblasts characterized by a well-developed 
cytoskeleton. Myofi  broblasts express α-smooth muscle actin 
(α-SMA), which is incorporated into actin stress fi  bers and 
  enables them to develop much higher mechanical forces (Hinz 
and Gabbiani, 2003). Hence, induction of α-SMA expression in 
fi  broblasts is a critical step in wound healing.
Besides growth factors and cytokines, bioactive lipids 
have been identifi  ed as important signal molecules, modulating 
infl  ammatory responses, cell growth, and tissue formation. 
However, the role of lipid-induced signaling and its contribution 
to wound healing is still poorly understood. We previously 
showed that sphingosine-1-phosphate (S1P) triggers a signal 
transduction cascade mediating nuclear translocation of the 
LIM-only protein Fhl2 in response to activation of the RhoA 
GTPase (Muller et al., 2000, 2002). We and others further iden-
tifi  ed the LIM-only protein Fhl2 as interacting with transcrip-
tion factors, including androgen receptor (Muller et al., 2002), 
serum response factor (SRF; Philippar et al., 2004; Purcell et al., 
2004), Jun, and Fos (Morlon and Sassone-Corsi, 2003), as well 
as with integrin receptors (Wixler et al., 2000; Samson et al., 2004) 
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A
fter skin wounding, the repair process is initiated 
by the release of growth factors, cytokines, and 
bioactive lipids from injured vessels and coagu-
lated platelets. These signal molecules induce synthesis and 
deposition of a provisional extracellular matrix, as well as 
ﬁ   broblast invasion into and contraction of the wounded 
area. We previously showed that sphingosine-1-phosphate 
(S1P) triggers a signal transduction cascade mediating 
nuclear translocation of the LIM-only protein Fhl2 in response 
to activation of the RhoA GTPase (Muller, J.M., U. Isele, 
E. Metzger, A. Rempel, M. Moser, A. Pscherer, T. Breyer, 
C. Holubarsch, R. Buettner, and R. Schule. 2000. EMBO J. 
19:359–369; Muller, J.M., E. Metzger, H. Greschik, 
A.K. Bosserhoff, L. Mercep, R. Buettner, and R. Schule. 2002. 
EMBO J. 21:736–748.). We demonstrate impaired cutane-
ous wound healing in Fhl2-deﬁ  cient mice rescued by trans-
genic expression of Fhl2. Furthermore, collagen contraction 
and cell migration are severely impaired in Fhl2-deﬁ  cient 
cells. Consequently, we show that the expression of α-smooth 
muscle actin, which is regulated by Fhl2, is reduced and 
delayed in wounds of Fhl2-deﬁ   cient mice and that the 
  expression of p130Cas, which is essential for cell migra-
tion, is reduced in Fhl2-deﬁ  cient cells. In summary, our data 
demonstrate a function of Fhl2 as a lipid-triggered signal-
ing molecule in mesenchymal cells regulating their migra-
tion and contraction during cutaneous wound healing.
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and signal transducers such as β-catenin (Martin et al., 2002). 
Fhl2 associates with integrins at focal adhesion sites and is 
translocated into the nucleus upon stimulation by serum or S1P 
to modulate transcriptional activity of numerous target genes. 
Because signifi  cant amounts of S1P and lysophos  phatidic acid 
are released from platelets during tissue repair (Yatomi et al., 
2000), we investigated the role of Fhl2 signaling in mesenchy-
mal cells during wound healing.
Results
Previous studies of Fhl2 in prostate cancer revealed its expres-
sion in the prostate cancer cells proper, but also in myofi  bro-
blast-like cells within the stroma (Muller et al., 2000, 2002). To 
confi   rm expression and regulation of Fhl2 in mesenchymal 
cells, we isolated primary embryonic mouse fi  broblasts and vi-
sualized Fhl2 expression and nuclear translocation in response 
to serum exposure. When fi  broblasts were starved in 0.5% FCS, 
and then exposed to 10% FCS for 24 and 48 h, respectively, we 
observed both signifi  cant up-regulation of Fhl2 mRNA and nu-
clear translocation of the respective protein (Fig. S1, available 
at http://www.jcb.org/cgi/content/full/jcb.200606043/DC1), as 
previously described (Muller et al., 2002). More importantly, 
we observed strong up-regulation of Fhl2 in α-SMA–positive 
mesenchymal cells of wounded skin (Fig. 1 A). A series of fi  ve 
different tissue specimens obtained 5–14 d after wounding were 
analyzed by Fhl2 immunostaining. In all cases, we observed 
very strong signals present in the cytoplasm and the nucleus 
of myofi  broblast-like cells of the granulation tissue, but not in 
differentiated fi  broblasts from normal skin (Fig. 1 A). The myo-
fi  broblasts are characterized by α-SMA and SM22 immuno-
reactivity and, importantly, double-immunostainings of tissue 
sections for both Fhl2 (Fig. 1 B, red stain) and α-SMA or SM22 
(Fig. 1 B, brown stain) indicated that the most abundant site 
of Fhl2 expression in the granulation tissue are indeed myo-
fi  broblasts. In contrast, keratinocytes did not reveal any Fhl2 
immunoreactivity. These results, along with data obtained from 
human skin biopsies in vivo and from serum stimulation of cell 
lines, indicated that Fhl2 is up-regulated in myofi  broblasts 
  during wound healing and that it shuttles into the nucleus in 
  response to exposure to bioactive lipids present in blood, as pre-
viously described (Muller et al., 2002; Morlon and Sassone-Corsi, 
2003; Philippar et al., 2004).
We applied punch biopsy wounds to skin and cutaneous 
muscle of wild-type (Fhl2
+/+) and Fhl2-defi  cient  (Fhl2
−/−) 
mice and conclusively found signifi  cant up-regulation of both 
Fhl2 mRNA and protein expression in Fhl2
+/+ mice during skin 
regeneration, with a maximum at 5 d after wounding (Fig. 2, 
A and B). In contrast, Fhl2
−/− mice lack Fhl2 mRNA and pro-
tein expression (Fig. 2, A and B). Intermediate levels of Fhl2 
were induced in wounds of mice carrying a SM22 promoter-
driven Fhl2 transgene in a Fhl2
−/− genetic background (Fhl2
−/−
tgSM22Fhl2). Interestingly, Fhl2
−/− mice revealed severely 
impaired wound healing because only 10% of skin wounds 
were closed after 5 d, compared with 40% in Fhl2
+/+ mice 
(Fig. 2 C). After 12 d, all wounds of Fhl2
+/+ mice were closed, 
whereas only 80% were closed in Fhl2
−/− mice. Importantly, 
the Fhl2
−/−tgSM22Fhl2 transgenic mice that express inter-
mediate Fhl2 mRNA and protein levels in a Fhl2
−/− genetic 
background, displayed a nearly wild-type phenotype, with 30 
and 90% wound closure at days 5 and 12, respectively, demon-
strating rescue of the wound closure phenotype of Fhl2
−/− mice. 
The same SM22Fhl2 transgene expressed in a Fhl2
+/+ back-
ground, however, did not infl  uence wound healing, indicating 
that the high levels of Fhl2 expression in Fhl2
+/+ mice are both 
necessary and suffi  cient for effi  cient wound healing. At each 
time point, 38–42 lesions were evaluated by measuring wound 
closure macroscopically, as well as by histological and immuno-
chemical staining of skin sections. Collectively, our data in-
dicate that the effi  ciency of wound closure correlates with the 
amount of Fhl2 mRNA and protein expression in wounds.
Fibroblasts play a key role in the formation of mechanical 
forces that lead to wound contraction, which is required to bring 
the wound margins together. Therefore, we were interested in 
Figure 1.  Expression and nuclear translocation of Fhl2 in myoﬁ  broblasts 
within human skin wounds. (A) Immunostaining of human wound tissue 
  reveals strong up-regulation of Fhl2 in α-SMA–positive myoﬁ  broblast-like 
cells present in dermal granulation tissue 5 d after wounding. (B) Double 
immunostaining of human wound tissue indicates that Fhl2 immunosignals 
(arrows, red AEC stain) label α-SMA– and SM22-positive myoﬁ  broblasts. 
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correlating the Fhl2 function with extracellular matrix remodeling 
and contraction. We analyzed the fi  broblast-mediated con-
traction of type I collagen gels as an in vitro model of tissue 
remodeling. Fibroblasts derived from Fhl2
−/− mice displayed a 
severe defect in collagen contraction, with a half-maximal con-
traction time of >60 h, compared with 10.4 h in Fhl2
+/+ cells 
(Fig. 3 A). The contraction of a collagen matrix was, in fact, 
so severely impaired in Fhl2
−/− cells that we were unable to 
measure exactly the half-maximal contraction time within the 
observation interval. Because bioactive lipids stimulate fi  bro-
blast-mediated collagen contraction (Yanase et al., 2000), we 
analyzed collagen contraction in the presence of S1P. This 
  resulted in a decreased half-maximal contraction time of 8.6 h 
for Fhl2
+/+ fi  broblasts (Fig. 3 A). In contrast, S1P did not stim-
ulate collagen contraction mediated by Fhl2
−/− fi  broblasts. 
Importantly, ectopic expression of Fhl2 in Fhl2
−/− fi  broblasts by 
transfection of an appropriate expression plasmid fully restored 
the capability to contract collagen (Fig. 3 A), demonstrating that 
Fhl2 is an essential component in this tissue remodeling assay.
During wound healing, mesenchymal cells differentiate 
upon stimulation by infl   ammatory cytokines into myofi  bro-
blasts, which produce high amounts of α-SMA and are involved 
in wound contraction in vivo (Hinz and Gabbiani, 2003). The 
early phase of wound healing is triggered by serum components 
released from injured blood vessels and degranulating platelets 
(Yatomi et al., 2000), which activate the transcription factor 
SRF (Chai and Tarnawski, 2002). SRF and Fhl2 interact physi-
cally (Philippar et al., 2004) and bind to the promoter of the 
SRF-responsive α-SMA gene. Degranulating platelets release 
large amounts of bioactive lipids, including S1P and lysophos-
phatidic acid, into wounds that, in turn, trigger nuclear trans-
location of Fhl2 (Muller et al., 2002). Therefore, we addressed 
Figure 2.  Delayed wound healing in Fhl2
−/− mice. 
Up-regulation of Fhl2 mRNA (A) and Fhl2 protein (B) in 
skin wounds 5 and 12 d after applying punch biopsies in 
Northern and Western blots, respectively. Fhl2
+/+ mice, 
Fhl2
−/− mice (Fhl2
−/−), and the rescue mouse strain carry-
ing a SM22-promoter Fhl2 transgene in an Fhl2
−/−genetic 
background (Fhl2
−/−tgSM22Fhl2) were used. Gapdh 
and β-actin served as loading controls. (C) Percentage 
of  entirely closed wounds in Fhl2
+/+,  Fhl2
−/−,  Fhl2
−/−-
  rescue, and Fhl2
+/+tgSM22Fhl2 mice after 5 and 12 d, 
respectively. 38–42 wounds for each genotype and time 
point were monitored by macroscopic inspection, and 
punch biopsies were veriﬁ  ed histologically. Error bars rep-
resent the SD.JCB • VOLUME 177 • NUMBER 1 • 2007  166
the question of whether Fhl2 may function as a transcrip-
tional cofactor of SRF in activating α-SMA expression during 
wound healing.
For these assays, we tested cells of different origin (epi-
thelial human embryonic kidney [HEK] 293 cells, mesenchymal 
stem cells, and fi  broblasts), which are devoid of endogenous 
Fhl2 expression or with a Fhl2 knockout genotype, respectively. 
These cells were cotransfected with SRF- and Fhl2-expression 
constructs, together with a reporter plasmid carrying an α-SMA 
promoter-driven luciferase gene. Although expression of Fhl2 
in HEK293 alone did not change reporter activity, we observed 
between two- and threefold activation in the mesenchymal cells 
(Fig. 3 B). SRF mediated an approximately fourfold increase of 
reporter expression in all cell lines. Importantly, expression of 
both SRF and Fhl2 resulted in approximately two- or threefold 
higher reporter activity than expression of SRF alone (Fig. 3 B), 
indicating coactivation of SRF-mediated transcriptional activity 
in all three cell lines.
We characterized α-SMA expression in myofi  broblasts 
during wound healing in Fhl2
−/− and Fhl2
+/+ mice. As ex-
pected, immunohistochemical staining revealed strong expres-
sion of α-SMA in myofi   broblasts of the granulation tissue 
Figure 3.  Fhl2 regulates ﬁ  broblast contractility 
and coactivates SRF-mediated 𝗂-SMA tran-
scription in wound healing. (A) Defective 
collagen contraction in Fhl2
−/− embryonic 
ﬁ   broblasts (top). Collagen contraction and 
stimulation in response to treatment with S1P 
were restored after retransfecting Fhl2 cDNA 
into Fhl2
−/− ﬁ  broblasts (bottom). Transfections 
were done in triplicate, with either empty vec-
tor (pcDNA3) or Fhl2 expression plasmid 
(Fhl2). SDs were <2% in all cases. (B) HEK293, 
Fhl2
−/− ﬁ  broblasts (MEFs), and Fhl2
−/− mesen-
chymal stem cells (MSCs) were transfected 
with an α-SMA promoter-driven luciferase re-
porter construct and expression plasmids for 
SRF and Fhl2. Bars indicate the fold induction 
of transfecting SRF, Fhl2, and both expression 
vectors versus the luciferase activity of the re-
porter plasmid. n = 3. Error bars represent the 
SD. (C) Cutaneous lesions 5 d after applying 
skin punch wounds to Fhl2
+/+ and Fhl2
−/− 
mice. Images show hematoxylin and eosin 
staining (HE, top) and immunohistochemical 
stainings for α-SMA expression (bottom). There 
is strong α-SMA reactivity in the granulation 
tissue of Fhl2
+/+, but not of Fhl2
−/−, mice be-
low the reepithelializing keratinocytes on top. 
Bar, 100 μm.IMPAIRED WOUND HEALING IN FHL2-DEFICIENT MICE • WIXLER ET AL. 167
below the wound surface at day 5 in Fhl2
+/+ mice, but only very 
weak signals in knockout animals (Fig. 3 C). Systematically 
scoring the intensity of α-SMA staining in 100 fi  broblasts be-
low every wound surface revealed signifi  cantly weaker staining 
in Fhl2
−/− mice (relative units, 1.25 ± 0.6 at day 5 and 1.4 ± 
1.0 at day 12, respectively) than in Fhl2
+/+ mice (relative units, 
2.6 ± 0.75 at day 5 and 2.0 ± 0.6 at day 12, respectively). The 
difference in α-SMA staining intensity was that it was statisti-
cally signifi  cant at day 5 (P < 0.001) and was still signifi  cant at 
day 12 (P < 0.1). Importantly, immunostainings of the trans-
genic SM22Fhl2 rescue mouse strain did not reveal any differ-
ence in α-SMA reactivity compared with Fhl2
+/+ mice. These 
results indicate that activation of α-SMA expression in myo-
fi  broblasts and wound closure occurred less effi  ciently and slower 
in Fhl2
−/− mice.
Cutaneous wound healing is inevitably associated with 
migration of mesenchymal precursor cells and their subsequent 
differentiation into myofi  broblasts. Within the fi  rst days after 
wounding, mesenchymal cells invade the wound to replace the 
clot and to form a granulation tissue. To address the question of 
whether Fhl2 infl  uences the migration capacity of such cells, 
we established mesenchymal stem cell lines from bone marrow 
of Fhl2
+/+ and Fhl2
−/− mice (Fig. 4 A). The morphology of dif-
ferent Fhl2
−/− clones was quite similar, but differed from that 
of Fhl2
+/+ clones. Fhl2
−/− cells showed a more epithelial-like 
form and had a less polar shape, often with many short actin 
stress fi  bers running in different directions. Fhl2
+/+ cells had 
a more fi  broblast-like form, with many fi  lopodial and lamelli-
podial structures. They displayed a well-organized actin cyto-
skeleton with long microfi   lament cables running across the 
whole cell body (Fig. 4 A), and Fhl2 was localized at focal ad-
hesion structures, as well as along the actin fi  laments. Analysis 
of the migration capacity revealed a motility defect of Fhl2
−/− 
cells (Fig. 4 B and Videos 1 and 2, available at http://www.jcb
.org/cgi/content/full/jcb.200606043/DC1). Fhl2
−/− cells showed 
much less activity in the formation of fi  lopodia or lamellipodia 
and, consequently, needed almost twice as much time to close 
a cell-free cleft in comparison with Fhl2
+/+ cells. (Fig. 4 B and 
Videos 1 and 2). Importantly, ectopic expression of a myc-
tagged Fhl2 protein (Fig. S2 A) rescued the impaired migration 
Figure 4.  Reduced motility of Fhl2
−/− mes-
enchymal stem cells. (A)  Fhl2
+/+,  Fhl2
−/−, 
and Fhl2
−/−-rescue stem cells were examined 
regarding shape (top), actin cytoskeleton or-
ganization, and distribution of Fhl2 protein 
(bottom). F-actin was visualized with Alexa 
Fluor 488–coupled phalloidin (green). Fhl2
+/+ 
and Fhl2
−/− cells were immunostained for Fhl2 
with the F4B2 monoclonal antibody, Fhl2
−/− 
rescued cells with the anti-myc 9E10 monoclo-
nal antibody. Bars,  50 μm. (B) Migration of 
Fhl2
+/+, Fhl2
−/−, and Fhl2
−/−-rescue mesen-
chymal stem cells. Cell migration on uncoated 
dishes into cell-free areas was photographed 
at 0 and 42 h.JCB • VOLUME 177 • NUMBER 1 • 2007  168
activity of the Fhl2
−/− cells (Fig. 4 B and Video 3). The ectopic 
expression of Fhl2 not only rescued the motility phenotype but 
also reverted the cell shape and actin cytoskeleton organization 
to that of Fhl2
+/+ stem cells (Fig. 4 A). Impaired cell motility 
was independent of the substrate on which the cells migrated 
(fi  bronectin, laminin-1, or no substrate) and of the cell origin. 
On uncoated dishes, cell movement was slower, with 10.8 ± 
1.4 μm/h for Fhl2
+/+, 5.8 ± 0.9 μm/h for Fhl2
−/−, and 9.6 ± 
0.9 μm/h for rescued mesenchymal stem cells. On fi  bronectin-
coated dishes, the migration velocity was 17.1 ± 0.7 μm/h for 
Fhl2
+/+, 8.8 ± 0.4 μm/h for Fhl2
−/−, and 12.0 ± 1.5 μm/h for 
Fhl2
−/−-rescued cells, respectively. The diminished migratory 
activity of Fhl2
−/− cells was not caused by changes of the in-
tegrin pattern on their surface, as Fhl2
+/+, Fhl2
−/−, and rescued 
cells all expressed equal amounts of integrin β1–containing 
receptors (Fig. S2 B). Like Fhl2
+/+ cells, the Fhl2
−/− or rescued 
cells attached equally well to proteins of the extracellular matrix, 
suggesting that different adhesion properties are not responsible 
for the reduced migratory capacity.
Interestingly, the impaired cell migration and the cyto-
skeletal changes of Fhl2
−/− cells remarkably resemble the pheno-
type of FAK-defi  cient cells (Ilic et al., 1995). In addition, it is 
known that FAK has to be activated for cell migration (Mitra 
et al., 2005). After adhesion to extracellular matrix molecules, 
FAK is autophosphorylated at tyrosine Y397, recruiting Src, 
which in turn phosphorylates FAK at additional Y residues, in-
cluding Y861, which serves as the binding site for p130Cas. 
Interaction of p130Cas and FAK leads to recruitment of multiple 
other proteins, fi  nally resulting in the formation of lamellipodia 
and cell migration (Playford and Schaller, 2004; Mitra et al., 
2005). Analysis of FAK tyrosine phosphorylation showed that the 
overall phosphorylation pattern was identical in Fhl2
+/+, Fhl2
−/−, 
and Fhl2
−/−-rescued mesenchymal cell lines (Fig S3, available 
at http://www.jcb.org/cgi/content/full/jcb.200606043/DC1). 
Only pY861, serving as the binding site for p130Cas, was 
slightly hyperphosphorylated in the Fhl2
−/− cells. We previ-
ously showed that Fhl2 directly binds to integrins (Wixler et al., 
2000) and FAK (Gabriel et al., 2004), and that it is localized at 
Figure 5.  Reduction of p130Cas expression 
in Fhl2
−/− cells. (A) p130Cas, Src, or FAK pro-
teins were immunoprecipitated from lysates of 
ﬁ  bronectin-stimulated Fhl2
+/+ or Fhl2
−/− cells 
and analyzed by immunoprobing for the pro-
teins indicated. (B) Recombinant expression of 
myc-Fhl2 in Fhl2
−/− cells reverses p130Cas 
expression. Immunoblot with anti-ERK1 anti-
body served as loading controls. 10 μg of 
total cell lysates were analyzed. (C) Expression 
control of p130Cas in Fhl2
−/− stem cells. Cells 
were infected with retroviruses containing the 
GFP vector or GFP+p130Cas. 48 h later the 
cells were harvested and one part was used 
for analysis of infection efﬁ   ciency by FACS-
scan (top) or by immunoblotting (bottom). Black 
curve of the FACSscan proﬁ  le,  noninfected 
cells; blue curve, GFP-vector–infected cells; 
red curve, GFP+p130Cas–infected cells. For 
immuno  blotting, 7.5 μg of total cell lysates were 
separated on 10% SDS-PAGE, and p130Cas 
and ERK1/2 (as loading controls) were de-
tected with speciﬁ  c antibodies. (D) The second 
part of infected cells, along with noninfected 
Fhl2
+/+ and Fhl2
−/− cells, was used for migra-
tion assays. Migration of cells on noncoated or 
on ﬁ   bronectin-precoated dishes was studied. 
The assays were performed twice with similar 
results. Only cell motility on noncoated dishes 
is shown. Error bars represent the SD. (E) Re-
duction of Rac activation in Fhl2
−/− cells (top) 
and increased Rac activation in p130Cas-
overexpressing Fhl2
−/− cells (bottom). The cells 
were serum-starved overnight, trypsinized, 
and plated for 15, 30, and 60 min on cell cul-
ture dishes precoated with 20 μg/ml ﬁ  bronectin. 
For precipitation of GTP-loaded Rac, cells were 
lysed in Triton X-100 lysis buffer, and 400 μg 
of protein lysates were rotated with GST-PAK3–
coated glutathione beads. The precipitates 
and the lysates were analyzed for the pres-
ence of Rac1 by SDS-PAGE and Western 
Blotting. The fold of Rac activation was esti-
mated densitometrically as the relative intensity 
of the GTP-Rac bands to the loading controls. 
Values at time point 0 were taken as unity.IMPAIRED WOUND HEALING IN FHL2-DEFICIENT MICE • WIXLER ET AL. 169
focal adhesion sites (Samson et al., 2004). Analysis of immuno-
complexes from lysates of Fhl2
+/+ and Fhl2
−/− cells showed 
that Fhl2 coimmunoprecipitated with FAK and p130Cas, but 
not with Src, when cells were plated on fi  bronectin-coated 
dishes (Fig. 5 A). Interestingly, the level of p130Cas was signifi  -
cantly reduced in Fhl2
−/− cells, whereas the amounts of FAK 
and Src were not altered (Fig. 5 A). Furthermore, as shown in 
Fig. 5 B, the level of p130Cas was similar to that of Fhl2
+/+ 
cells when the Fhl2 protein was reexpressed in Fhl2
−/− cells.
Next, quantitative real-time PCR experiments were per-
formed to study whether the changes in p130Cas expression 
levels result from differences in mRNA expression. Amplifi  ca-
tion curves for p130Cas and, as a reference gene, cyclophilin, 
were obtained with template cDNA from Fhl2
+/+ and Fhl2
−/− 
mesenchymal stem cells. Each curve shown in the Fig. S4 A (avail-
able at http://www.jcb.org/cgi/content/full/jcb.200606043/DC1) 
represents the mean of three replicates from a single cDNA 
sample. The amplifi  cation of p130Cas cDNA was delayed 
in Fhl2
−/− cells compared with Fhl2
+/+ cells, indicating a 
lower p130Cas mRNA amount. The difference between the 
average Ct-value of p130Cas and cyclophilin (∆Ct) was calcu-
lated for both cell lines. These values were compared (∆∆Ct), 
and the relative amount of p130Cas mRNA was calculated 
(2
-∆∆Ct) and diagrammed (Fig. S4 B). In summary, our data 
clearly indicate that Fhl2 knockout cells express roughly two-
fold lower p130Cas mRNA levels.
Recruitment of p130Cas subsequently leads to activation 
of Rac and cell migration (Playford and Schaller, 2004; Mitra 
et al., 2005). Therefore, we asked whether expression of p130Cas 
in Fhl2
−/− mesenchymal stem cells would be able to rescue the 
defect in cell migration. Knockout stem cells were infected with 
retroviruses expressing either p130Cas along with GFP or GFP 
alone as a control. The p130Cas and GFP genes were connected 
by an internal ribosomal entry-site sequence. Evaluation of 
GFP-labeled cells indicated that the infection effi  ciency was 
94.1 and 95.2%, respectively (Fig. 5 C, left). Consistently, West-
ern blots indicated robust expression of p130Cas in the knock-
out cells (Fig. 5 C, right). Analysis of cell motility revealed that 
the migratory capacity of Fhl2
−/− cells that overexpressed 
p130Cas was enhanced in comparison with Fhl2
−/− cells, but 
did not reach the velocity of Fhl2
+/+ cells. These results were 
obtained independently of whether cells migrated on noncoated 
or on fi  bronectin-coated surfaces (Fig. 5 D). Thus, reexpression 
of p130Cas rescued the migratory phenotype of Fhl2
−/− cells, 
but not entirely to the level of Fhl2
+/+ cells.
Finally, we asked whether changes in expression of 
p130Cas resulted in different levels of Rac activation. There-
fore, Fhl2
+/+, knockout, and Fhl2
−/− cells stably expressing 
p130Cas or the empty vector were assayed for Rac activity. The 
cells were serum-starved overnight, trypsinized, and plated for 
15, 30, or 60 min, respectively, on cell culture dishes precoated 
with 20 mg/ml fi  bronectin. For precipitation of GTP-loaded 
Rac, cells were lysed in Triton X-100 lysis buffer, and 400 mg 
protein were rotated with GST-PAK3–coated glutathione beads. 
Although the activation kinetics slightly varied in separate 
  experiments, a reproducible difference in the Rac activation 
between Fhl2
+/+ and Fhl2
−/− cells was observed. Data shown in 
Fig. 5 E clearly indicate that knockout cells activate Rac less 
effi  ciently than Fhl2
+/+ cells, and that Fhl2
−/− cells reconstituted 
with p130Cas restore their capability to activate Rac in response 
to attachment to fi  bronectin.
Discussion
Previous studies, mainly based on cell lines in vitro, established 
Fhl2 as a serum-responsible signal transducer shuttling in re-
sponse to SP1 and lysophosphatidic acid from the cell mem-
brane into the nucleus, where it functions as a nuclear coactivator 
of transcription factors. However, only few transcriptional tar-
gets, including Fhl2 itself, were described, and the function 
of Fhl2 signaling in vivo is much less explored. Although a 
function of Fhl2 in promoting differentiation of myoblasts was 
suggested (Martin et al., 2002), Fhl2 knockout mice developed 
only a mild phenotype with bone formation defects and an 
increased sensitivity in respect to a hypertrophic response to 
β-adrenergic stimulation in the heart (Kong et al., 2001; Bai 
et al., 2005; Gunther et al., 2005; Lai et al., 2006).
Data presented in our study indicate that Fhl2 further me-
diates nonredundant signaling during wound healing. Fhl2
−/− 
mice clearly revealed delayed wound healing, reduced migra-
tion of mesenchymal precursor cells, delayed activation of 
α-SMA, and impaired wound contraction. The Fhl2 protein is 
activated in dermal fi  broblasts after release of bioactive lipids in 
wounded tissue and, indeed, we show that Fhl2 regulates the 
expression of α-SMA by coactivation of SRF, and thereby the 
contractility of the granulation tissue. Therefore, it seems that 
nuclear shuttling and transcriptional coactivation of Fhl2 devel-
oped as a signaling pathway mediating rapid adaptation of cells 
and tissues in response to pathological stress conditions. Our 
data further indicate that Fhl2 signaling is cell-type specifi  c and 
different from its function in cardiac muscle cells, where it neg-
atively regulates expression of SMA (Philippar et al., 2004).
In addition, Fhl2 interacts with proteins of focal adhesion 
structures at the membrane or cytosolic level, and we provide 
fi  rst evidence that because of this interaction Fhl2 regulates cell 
motility and contractility. Contraction of the granulation tissue 
facilitates wound closure by bringing the wound margins 
together. Effi  cient contraction of myofi  broblasts requires a well-
developed cytoskeleton, which is established by expression of 
α-SMA and its incorporation into actin stress fi  bers (Hinz and 
Gabbiani, 2003). Hence, expression of α-SMA by skin fi  bro-
blasts is a critical step in wound healing. Interestingly, our data 
for the fi  rst time provide a mechanistic link between release of 
the bioactive lipids S1P and lysophosphatidic acid from plate-
lets during clotting and wound healing and the contractile 
activity of the granulation tissue. These substances trigger, in a 
Rho-dependent manner, nuclear shuttling of Fhl2 (Muller et al., 
2002) where it acts as a coactivator of α-SMA transcription. 
Consistent with these data, we further demonstrated that in the 
absence of Fhl2, the contractile forces of fi  broblasts are dramat-
ically reduced and that this defect can be rescued by expression 
of exogenous Fhl2 protein.
It is well known that FAK plays a key role in cell migration. 
It is activated upon integrin engagement and recruits several JCB • VOLUME 177 • NUMBER 1 • 2007  170
  cytosolic proteins that drive cell migration. We show that the 
expression of the downstream signaling molecule p130Cas, 
which regulates the activity of the Rac GTPase, and hence, cell 
migration, is down-regulated in Fhl2
−/− cells. Our data, how-
ever, also indicate that the mechanism by which Fhl2 regulates 
cell migration is more complex and cannot be reduced just 
to the level of p130Cas protein, as its overexpression did not 
  restore migration velocity of mesenchymal cells to the full level 
of Fhl2
+/+ cells. Thus, it appears that Fhl2 activation in me-
senchymal cells after wounding regulates different effector 
functions of activated FAK. A separate study of our group 
provided evidence that Fhl2 is also involved in organization of 
focal adhesion structures and in regulation of matrix assembly 
(unpublished data).
In summary, we show for the fi  rst time that Fhl2
−/− 
mice display a cutaneous wound-healing phenotype that can 
be rescued by ectopic expression of Fhl2. Our data demon-
strate reduced expression of α-SMA and p130Cas and, sub-
sequently, less effi  cient activation of Rac in Fhl2
−/− cells, which 
lead to severe defects in collagen contraction and migration. 
Thus, lipid-triggered Fhl2 signaling is mechanistically involved 
in regulating wound healing and may represent a new thera-
peutic target.
Materials and methods
Fhl2
−/− and transgenic mice
Fhl2
−/− mice were provided by R. Bassel-Duby (University of Texas South-
western Medical Center, Dallas, TX) and published previously (Kong 
et al., 2001). For the generation of transgenic mice, the human Fhl2 
cDNA was coupled with a 1.4-kb SM22α promoter (Jain et al., 1998) 
and  animals were obtained according to published procedures (Jager 
et al., 2003). Genotyping was done by PCR analysis from tail genomic 
DNA using the primer pairs 5′-G  A  C  T  G  C  T  C  C  A  A  C  T  T  G  G  T  G  T  C  T  T  T  C  -3′ and 
5′-T  C  C  C  G  C  A  G  G  A  T  G  T  A  C  T  T  C  T  T  G  C  -3′ in 35 ampliﬁ   cation cycles (95°C 
for 30 s, 54°C for 30 s, and 72°C for 30 s). All animals were maintained 
in a pure C57BL/6 background, and subpairs were used for the wound-
ing experiments.
Wound-healing experiments
48 6-wk-old mice (18 Fhl2
+/+, 18 Fhl2
−/−, and 12 transgenic mice) were 
used. 2–4 0.6-cm punch wounds, including the skin and cutaneous mus-
cle, were cut into each mouse and left to heal by secondary intention, 
essentially as previously described (Ashcroft et al., 1999). At days 0, 5, 
and 12, wounds were dissected and parafﬁ  n-embedded for histology or 
snap-frozen in liquid nitrogen for RNA and protein extraction. All experi-
ments were performed in compliance with animal welfare regulations 
(Permission No. 50.203.2-BN12, 12/02 by the Regierungspräsidium, 
Cologne, Germany).
Cell culture and collagen contraction assays
Mouse embryonal ﬁ  broblasts were obtained by standard procedures and 
maintained in DME (Invitrogen) supplemented with 100 U/ml penicillin, 
10 μg/ml streptomycin, and 10% FCS (Invitrogen). Transient transfection 
of ﬁ  broblasts was done using the Amaxa system (Amaxa) with transfection 
efﬁ  ciency  >50% measured by GFP expression (Hamm et al., 2002). 
Collagen contraction was performed as previously described (Bell et al., 
1979; Grinnell, 2000). In brief, 250 μl of ﬁ  broblast suspension (10
6 cells/ml) 
were added to 3 ml collagen type I solution (3 mg/ml) and placed into a 
30-mm Petri dish (Greiner). Contraction of the developing collagen sponge 
was determined by measuring the diameter every 1 h.
Mesenchymal stem cells were derived from bone marrow cells of 
4-wk-old C57BL/6 Fhl2
+/+ or Fhl2
−/− mice as previously published (Park 
et al., 2006). The expanded cells had a doubling time of  35 h and were 
positive for CD34, c-kit, sca1, Thy1, and CD13, and negative for CD45, 
CD10, and CD31 marker as determined by PCR. According to these mark-
ers and to their potency to differentiate into osteogenic, chondrogenic, and 
adipogenic lineages, we identiﬁ  ed them as mesenchymal cell lineages. 
The cells were maintained in a mixture of DMEM and MCDB-201 medium 
supplemented with 2% FCS, 10 ng/ml EGF (Sigma-Aldrich), 10 ng/ml 
PDGF (R&D Systems), 1,000 U/ml of mouse LIF (CHEMICON Inter-
national, Inc.), 1× insulin–transferrin–selenium mixture (Sigma-Aldrich), 
and 10
−9M dexamethasone (Sigma-Aldrich). The Fhl2
−/− rescue cells were 
obtained by infection of Fhl2
−/− cells with retroviruses containing a myc-
tagged human Fhl2, as we previously described (Samson et al., 2004).
Northern and Western blots
Total cellular RNA was extracted from harvested cells or homogenized 
wound specimens by lysis in guanidinium isothiocyanate. 10 μg was sepa-
rated by electrophoresis in a 1.2% agarose/formaldehyde gel, transferred 
to a nylon membrane (Hybond N
+; GE Healthcare), and probed with 
radiolabeled Fhl2 cDNA. Soluble protein lysates were extracted from cells 
or homogenized wound specimens in 150 mM NaCl, 10 mM Tris, pH 7.2, 
0.1% SDS, 1% Triton X-100, and 1% deoxycholate and 5 mM EDTA and 
centrifuged at 13,000 g for 20 min at 4°C. 15 μg of protein lysates were 
denatured at 90°C for 10 min, run on 12% SDS-PAGE gels, and electroblotted 
to a PVDF membrane (Roti-PVDF; Roth GmbH) using standard protocols. 
After blocking in 5% nonfat dry milk/PBST for 2 h, the membranes were in-
cubated for 1 h with a monoclonal anti-Fhl2 antibody (dilution 1:2,000), 
washed, incubated with horseradish peroxidase–conjugated secondary 
antibody (dilution 1:1,000; DakoCytomation), and developed using ECL 
chemiluminescence (GE Healthcare). As a control, blots were probed 
with a primary anti–β-Actin antibody (dilution 1:5,000; DakoCytomation). 
Images were captured on ﬁ  lm, digitized, and if needed, minor linear ad-
justments in contrast were made using Photoshop software (Adobe).
Quantitative real-time PCR
Total RNA was extracted with the RNeasy kit (QIAGEN) from two indepen-
dent samples of Fhl2
+/+ and Fhl2
−/− stem cells, respectively. Reverse tran-
scription of RNA (1.5 μg) was performed with oligo(dT) primers and 
RevertAid H Minus M-MuLV reverse transcriptase (Fermentas MBI). For PCR 
ampliﬁ  cation of cDNA, speciﬁ  c primers (MWG) were used to detect differ-
ences in the expression levels of p130Cas; primers for murine p130Cas 
were chosen according to Jayanthi et al. (2002). Primers for the reference 
gene cyclophilin were as follows: 5′-C  C  A  C  C  G  T  G  T  T  C  T  T  C  G  A  C  A  T  -3′ (up-
stream) and 5′-C  A  G  T  G  C  T  C  A  G  A  G  C  T  C  G  A  A  A  G  -3′ (downstream). The PCR 
reactions were done in triplicate for each cDNA after the Stratagene proto-
col with 2× Brilliant SYBR Green QPCR Master Mix (Stratagene), with pre-
heating at 95°C for 10 min; 40 cycles of 95°C for 30 s, 60°C for 1 min, 
and 72°C for 30 s; and 95°C for 1 min, 60°C for 30 s, and 95°C for 30 s. 
MxPro Software (Stratagene) was used for analysis.
Immunostainings and acquisition of images
4-μm tissue slides were cut from formalin-ﬁ   xed and parafﬁ  n-embedded 
wound specimens and used for staining with hematoxylin and eosin or by 
immunohistochemistry. Indirect immunohistochemistry was done by the 
  avidine-biotin method, as previously described (Friedrichs et al., 2005). 
Primary antibodies were anti–human α-SMA (1:25 dilution; DakoCytomation), 
anti-SM22 (1:100 dilution; DakoCytomation), anti–cytokeratin-5 (1:100 
dilution; DakoCytomation), and anti–collagen type I (1:100 dilution; ICN 
Biochemicals). Slides were incubated with a secondary goat anti–mouse 
serum (dilution 1:200; DakoCytomation), reacted with the ABC kit (Vector 
Laboratories), and peroxidase activity was visualized with 3-amino-9-
  ethylcarbazole (Sigma-Aldrich). Double immunostaining with a second 
  alkaline phosphatase–labeled antibody (DakoCytomation) was done as 
previously described (Friedrichs et al., 2005). Pictures were taken by 
using a light microscope DM LB2 (Leica) and the analysis system software 
Diskus (Hilgers).
For immunoﬂ  uorescence staining, 5 × 10
5 ﬁ  broblasts were seeded 
in chamber slides (Nunc), grown to 75% conﬂ  uency, and incubated for 
48 h in medium containing 10 or 0.5% FCS. Indirect immunoﬂ  uorescence 
staining was done as previously described (Muller et al., 2002), using rab-
bit anti-Fhl2 antibody (1:300), anti-Fhl2 mAb clone F4B2 (Samson et al., 
2004), or anti-myc mAb derived from clone 9E10 (American Type Culture 
Collection). Cell images were taken using an Axiovert 2000 ApoTome 
  microscope with an AxioCam digital camera and AxioVision software 
(Carl Zeiss MicroImaging, Inc.).
Cell transfections and luciferase assays
Transfections of 293 cells and luciferase assays were performed as previ-
ously described (Muller et al., 2002). 500 ng of the reporter plasmid 
pSM8pGL3 were cotransfected with expression plasmids coding for SRF IMPAIRED WOUND HEALING IN FHL2-DEFICIENT MICE • WIXLER ET AL. 171
(2.5 ng) and Fhl2 (5 ng pCMX-Fhl2) as indicated. Transfections of Fhl2
−/− 
ﬁ   broblasts were performed with Lipofectamine (Invitrogen), and transfec-
tions of Fhl2
−/− stem cells were performed with Fugene 6 (Roche) as recom-
mended by the manufacturers. Relative light units were normalized to protein 
concentration using the Bradford dye assay (Bio-Rad Laboratories). For con-
struction of pSM8pGL3, the α-SMA promoter and the ﬁ  rst intron (SMP8; 
a gift from E.P. Smith, University of Cincinnati College of Medicine, Cincinnati, 
OH) were cloned in pGL3 (Promega). SMP8 contains −1,074 bp of the 
5′- ﬂ  anking region, 63 bp of 5′-UT, and the 2.5-kb ﬁ  rst intron of the α-SMA.
For generation of p130Cas retrovirus stocks, the cDNA of human 
p130Cas (a gift from K.H. Kirsch, Boston University Medical School, 
Boston, MA) was cloned into the bicistronic retroviral pEGZ vector before 
the internal ribosomal entry-site sequence and the GFP gene. After transfec-
tion of Phoenix virus-producer cells (Orbigen, Inc.) with pEGZ vector alone 
or pEGZ-p130Cas, the cells were selected for zeocin resistance, and 
supernatants from conﬂ  uent monolayers were used as retroviral stocks.
Cell migration assay
Cell migration studies were performed essentially as previously described 
(Lavrovskii and Razvorotnev, 1976). In brief, 5 × 10
3 cells in 0.8 ml of 
DMEM with 10 ng/ml EGF and PDGF were plated onto 48-well plates, 
which were precoated with ﬁ  bronectin, laminin-1, or nothing and blocked 
with 1% BSA. To produce a cell-free “window,” 1-mm-thick steel plates 
were inserted into wells before seeding the cells and were removed again 
after the cells had been attached to the bottom. This method has the advan-
tage over the frequently used “scratch window” assay in that the substrate 
in the window is not destroyed. The migration was monitored by inverted 
microscopy at the times indicated. For videos, the scratch assay was used.
Flow cytometry
10
5 cells were suspended in FACS-PBS (PBS containing 2% FCS and 
0.02% NaN3). Cells were incubated with integrin anti-β1 Abs (clone 
9EG7; BD Biosciences) for 20 min on ice, washed twice with FACS-PBS, 
and incubated with Cy2-conjugated secondary antibodies (DakoCyto-
mation) for additional 15 min. After washing the cells, measurements were 
performed with a FACSCalibur ﬂ  ow cytometer (BD Biosciences).
Statistics
For all statistical analyses, the Cochran-Armitage trend test was used and 
a P-value <0.05 was considered statistically signiﬁ  cant. To quantify the 
α-SMA immunohistochemical staining results, the following scoring system 
was applied: no staining, 0; weak staining, 1; moderate staining, 2; maximal 
staining, 3. 100 cells of each sample were evaluated.
Online supplemental material
Fig. S1 shows that Fhl2 mRNA is serum-inducible in embryonic mouse 
ﬁ   broblasts and that Fhl2 translocates into the nucleus and along the 
actin cytoskeleton in response to FCS. Fig. S2 shows the migration 
activity of Fhl2
+/+, Fhl2
−/−, and rescued mesenchymal stem cells (Videos 
1–3 are time-lapse movies correlating to Fig. S2). Fig. S3 shows that 
the absence of Fhl2 does not inﬂ   uence FAK autophosphorylation after 
adhesion of stem cells to ﬁ  bronectin. Fig. S4 shows results from real-time 
qRT-PCR, indicating that Fhl2
−/− cells express reduced levels of p130Cas 
mRNA. Online supplemental material is available at http://www.jcb
.org/cgi/content/full/jcb.200606043/DC1.
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